Sign in

    Chee Tiong Ooi • Guggenheim Securities

    Chee Tiong Ooi is a Vice President and Equity Research Analyst at Guggenheim Securities, specializing in coverage of the U.S. biopharmaceutical and healthcare sectors. He is known for providing in-depth analysis on a range of public biotech and pharmaceutical companies, contributing investment recommendations and research used by institutional clients. Ooi began his career in equity research after obtaining his professional securities licenses, including FINRA Series 7 and Series 63 registrations, and has been recognized for his detailed fundamental research and rigorous due diligence. Prior to joining Guggenheim Securities, he gained experience at other leading financial institutions, developing a track record of actionable investment insights for his coverage universe.

    Chee Tiong Ooi's questions to TTEC Holdings Inc (TTEC) leadership

    Chee Tiong Ooi's questions to TTEC Holdings Inc (TTEC) leadership • Q1 2025

    Question

    Chee Tiong Ooi asked if specific customer conversations indicated a weakening demand environment and questioned if there was any evolution in like-for-like pricing due to competition or client budget constraints.

    Answer

    CEO Kenneth Tuchman noted that the primary sign of caution is that new contract sizes are starting smaller, though he is confident they will grow with successful execution. He attributed this to clients taking a phased approach amid economic uncertainty. On pricing, Tuchman stated that while some competitors compete on price, TTEC maintains its pricing discipline. He believes the market is rationalizing and consolidating, which favors quality providers over those who 'buy' business, and TTEC will walk away from deals that don't meet its profitability standards.

    Ask Fintool Equity Research AI